Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 6, 2011

Opsona Awarded €5.9M EC Grant for Clinical Trials of mAB in Solid Organ Transplantation

  • Opsona Therapeutics won a €5.9 million (about $8.8 million) European Commission grant to fund clinical development of its lead candidate OPN-305 in solid organ transplantation. The Framework 7 award will involve establishing a European consortium of research and clinical groups known as MABSOT (monoclonal antibody solid organ transplantation).

    The initial clinical trial, due to start this year, will evaluate OPN-305 in preventing delayed graft function in renal transplant patients. Pending results from the Phase I trial, a prospective placebo-controlled Phase II study in the prevention of delayed graft function could begin during 2012, Opsona says.  

    OPN-305 is a fully humanized anti-TLR antibody designed to reduce pro-inflammatory cytokine production associated with heart and kidney diseases. The firm claims positive preclinical data has already been generated in multiple models of diseases including cardiac and kidney ischemia/reperfusion injuries, sepsis, as well as ex vivo models of human rheumatoid arthritis.

    Opsona is developing a platform of small molecules, monoclonal antibodies, and biologics that target immune system activity. The firm’s preclinical programs include an inflammasome project focused on the development of inhibitors of 1L-1β production.

    Its OpsoVac™ TLR platform, originally licensed from Trinity College, Dublin aims to boost the effectiveness of TLR agonist therapy by co-administering molecules that inhibit T-regulatory cells. The firm claims research at Trinity College has demonstrated that contrary to current dogma, TLR ligands promote the induction of regulatory T cells and anti-inflammatory mediators such as IL-10, TGF-β, and PGE2, which can exacerbate immunosuppressive conditions in patients with cancer or chronic infections and thus effectively counteract the benefits of TLR-based therapy.  Opsona aims to develop the OpsoVac platform through partnerships and is already working with CSL on a collaboration focused on identifying novel vaccine adjuvant formulations.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »